recent tweets

Coronavirus Vaccine Will Bypass Safety Testing


STORY AT-A-GLANCE

  • Researchers are foregoing some of the normally required safety testing in order to get a coronavirus vaccine out as soon as possible. The biotech company Moderna is also relying on a novel manufacturing technique to produce their genetically engineered coronavirus vaccine in record time
  • Moderna is using synthetic mRNA to instruct DNA to produce the same kind of proteins COVID-19 uses to gain access into our cells. The idea is that your immune system will learn to recognize and kill the real virus
  • It will still be at least a year before the vaccine, if successful in limited human trials, will be available to the public. But that’s a significantly shorter wait time than the 15 to 20 years it normally takes to bring an experimental vaccine to market
  • Fast-tracking vaccine development and licensure has considerable risks. It might be ineffective (which is typically the case for the seasonal influenza vaccine), or it might cause serious side effects (as was the case with the fast-tracked H1N1 swine flu vaccine in 2009), or it just might worsen infection rather than prevent it
  • The fast-tracked ASO3-adjuvanted H1N1 swine flu vaccine Pandemrix (used in Europe but not in the U.S. in 2009-2010) has been causally linked to childhood narcolepsy, which abruptly skyrocketed in several countries after its release

Safety testing for vaccines typically leaves much to be desired to begin with, but when it comes to fast-tracked pandemic vaccines, safety testing is accelerated and becomes even more inadequate. It looks like that will be the case with plans underway to fast-track a COVID-19 vaccine to market.

As reported by STAT News,1 researchers are foregoing some of the normally required safety testing in order to get a genetically engineered coronavirus vaccine out in record time. What’s more, at least one vaccine manufacturer is relying on an entirely novel technique to produce their coronavirus vaccine in partnership with the National Institutes of Health, while by-passing traditional animal testing before conducting human clinical trials. STAT News reports:2

“‘I don’t think proving this in an animal model is on the critical path to getting this to a clinical trial,’ said Tal Zaks, chief medical officer at Moderna, a Cambridge, Mass.-based biotech that has produced a Covid-19 vaccine candidate at record speed …

Yet ethicists aren’t so sure that the eventual benefits of rushing this unproven vaccine into clinical trials will outweigh the risks. ‘Outbreaks and national emergencies often create pressure to suspend rights, standards and/or normal rules of ethical conduct.

Often our decision to do so seems unwise in retrospect,’ wrote Jonathan Kimmelman, director of McGill University’s biomedical ethics unit, in an email to STAT.

The question is complicated by the newness of the science at play. The technology that has allowed Moderna to craft an experimental vaccine so fast has not yielded a single immunization that’s made it to market so far.

It’s a trendy idea: Instead of injecting people with a weakened pathogen or proteins from the surface of a pathogen, so that our bodies will learn to fight off such infections in the future, scientists are betting on a kind of genetic hack, a lab-made concoction that gets the body to produce its own virus-like bits which it will then train itself to combat.”

Fear Surrounding Pandemics Makes for Good Testing Grounds

Ethical questions really should be in the forefront of everyone’s mind, considering pandemic hysteria can easily make people take risks they normally might never consider.

Right now, the British company hVIVO,3 which conducts influenza research, is offering healthy volunteers £3,500 (approximately $4,500) in exchange for being infected with a mild coronavirus (strains 0C43 and 229E specifically), both of which cause milder symptoms than COVID-19 and have been in circulation for quite some time.4,5

Infected volunteers will receive antiviral medications and undergo testing in the hopes of finding something that will assist researchers in developing a vaccine against COVID-19. Moderna, however, is using a technology to develop a vaccine that has never been approved by the U.S. Food and Drug Administration.

Moderna is using synthetic messenger RNA (mRNA) to instruct DNA to produce the same kind of proteins COVID-19 uses to gain access into our cells. As reported by STAT News, the idea is that “Once those … dummy virus particles are there … our bodies will learn to recognize and clobber the real thing.”

Moderna is partnering with the National Institute of Allergy and Infectious Diseases (NIAID) and started recruiting healthy volunteers March 3, 2020.6 In all, 45 men and non-pregnant women between the ages of 18 and 55 will be paid $1,100 to receive two injections of the vaccine, 28 days apart.

The side effects at three different dosages will be evaluated. These clinical trials are taking place before there’s any scientific evidence that the vaccine actually works as intended and doesn’t cause severe side effects in animals.

Considering COVID-19 infection has a high survival rate, with 80% suffering asymptomatic or only mild illness,7 is it really wise to use this outbreak as a testing ground for experimental, untested vaccine manufacturing methods?

Originally appeared at: Mercola

Trending topic